DV
Dividend Vision

KLRA — Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. (KLRA)

Total return is 12.1% over the past 0.3 years, 1.2 points ahead of SPY at 10.9%.

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions, with a pipeline including injectable peptides, oral peptides, and oral small molecules such as KAI-9531 (a GLP-1/GIP receptor dual agonist) and KAI-7535 (an oral GLP-1 receptor agonist). As an early-stage biotech company, it does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development with a focus on metabolic disease treatments, though investors should be aware of the significant risks associated with development-stage companies.

KLRA key facts

Asset type
Stock
Asset class
Equity
Inception date
04/16/2026
Distribution frequency
None
Last close
$17.94
Market cap
$2,324,407,040
Average volume
335985.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.25